XML 41 R29.htm IDEA: XBRL DOCUMENT v3.24.3
Nature of business (Details) - USD ($)
$ in Thousands
Sep. 03, 2024
Sep. 30, 2024
Dec. 31, 2023
Accumulated deficit   $ (291,697) $ (261,182)
Cash, cash equivalents, and marketable securities   $ 345,400  
Novartis Pharma, AG | Option and License Agreement      
Upfront payment $ 15,000